Third-Party Natural Killer Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Third-Party Natural Killer Cells, covering 2026-02-10 to 2026-02-10. Get the full timeline:
Most recent: Clinical Trial Update: Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma [Phase 1]